Celularity 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
taniraleucel (CYNK-001) / Celularity, United Therapeutics Corp
CYNK001COVID, NCT04365101: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Active, not recruiting
1/2
86
US
CYNK-001
Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)
Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
12/21
06/22
NCT04309084: Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Active, not recruiting
1
29
US
CYNK-001
Celularity Incorporated
Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
01/23
04/23
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Terminated
1
27
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
01/23
04/23
CYNK-101 / Celularity
NCT05207722: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated
1/2
1
US
CYNK-101, Pembrolizumab, Keytruda®, Trastuzumab, Herceptin®, Recombinant Human Interleukin-2, proleukin, Cyclophosphamide, cytoxan, Fludarabine, fludara, Mesna
Celularity Incorporated
Metastatic HER2 Positive Gastroesophageal Junction Cancer
02/24
02/24
APPL-001 / Celularity
No trials found
CAR19-CYNK / Celularity
No trials found
allogeneic ROR1-targeted CAR-T / Oncternal Therap
No trials found
allogeneic ROR1-targeted CAR-NK cell therapy / Oncternal Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
taniraleucel (CYNK-001) / Celularity, United Therapeutics Corp
CYNK001COVID, NCT04365101: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Active, not recruiting
1/2
86
US
CYNK-001
Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM)
Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
12/21
06/22
NCT04309084: Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Active, not recruiting
1
29
US
CYNK-001
Celularity Incorporated
Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs
01/23
04/23
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Terminated
1
27
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
01/23
04/23
CYNK-101 / Celularity
NCT05207722: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated
1/2
1
US
CYNK-101, Pembrolizumab, Keytruda®, Trastuzumab, Herceptin®, Recombinant Human Interleukin-2, proleukin, Cyclophosphamide, cytoxan, Fludarabine, fludara, Mesna
Celularity Incorporated
Metastatic HER2 Positive Gastroesophageal Junction Cancer
02/24
02/24
APPL-001 / Celularity
No trials found
CAR19-CYNK / Celularity
No trials found
allogeneic ROR1-targeted CAR-T / Oncternal Therap
No trials found
allogeneic ROR1-targeted CAR-NK cell therapy / Oncternal Therap
No trials found

Download Options